ºÚÁÏÍø

ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
ºÚÁÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

ºÚÁÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Depression improvement among patients with HIV and endocrine dysfunction after hormone therapy

4th International Congress on Infectious Diseases

Fereshteh Ghiasvand, Ladan Abbasian, Afarin Rahimi-Movaghar, Alireza Esteghamati, Mehrdad Hasibi and Nahid Zakerzadeh

Tehran University of Medical Sciences, Iran

ScientificTracks Abstracts: J Infect Dis Ther

DOI:

Abstract
Background: Endocrine diseases are common among men living with HIV (MLWH) known as curable etiology of depression. Depression impedes adherence to treatment and perceived quality of life. Aim: The objective of this study was to evaluate depression after medical treatment of underlying endocrine diseases among Iranian MLWH. Materials & Methods: We recruited a convenient sample of 296 MLWH at a referral HIV clinic from April 2013 to March 2014. In phase I (cross-sectional evaluation), all patients were interviewed using the beck depression inventory (BDI- II) questionnaire. In phase II, participants with moderate to severe depression (n=110, scores �21) were evaluated for endocrine diseases (evaluations: total testosterone, triiodothyronine, thyroxine, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone and serum cortisol). 11 patients diagnosed with hypogonadism were finally considered for hormone replacement therapy. We reevaluated changes in depressive symptoms with BDI-II. Results: From 237 participants, 136 (75%) had BDI scores �21; 110 participated in the endocrine evaluations. Secondary hypogonadism (total testosterone �2.8 nmol/l; LH, FSH: normal) was the only observed abnormality in 10% (n=11) of the patients and hormone replacement was prescribed to seven of them for three months. All patients were re-evaluated for depression; significant changes were observed in final scores (p=0.027). Conclusions: Evaluation and treatment of hypogonadism can help clinicians to reduce or control depression among people living with HIV; hence improving treatment compliance and patient outcomes.
Biography

Fereshteh Ghiasvand is an Assistant Professor of Infectious Diseases department at Tehran University of Medical Sciences.

Email: ghiasvand_62@yahoo.com

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top